Journal of Hepatology最新文献

{"title":"The EASL Congress 2026 will take place 27-30 May in Barcelona (Spain). Submit your abstract by 6 January!","authors":"","doi":"10.1016/S0168-8278(25)02505-X","DOIUrl":"10.1016/S0168-8278(25)02505-X","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"83 5","pages":"Page ii"},"PeriodicalIF":33.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145288247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Autoimmune Hepatitis be diagnosed and treated without liver biopsy?","authors":"Mahmut Polat, Staffan Wahlin, Cumali Efe","doi":"10.1016/j.jhep.2025.09.032","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.032","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors contribution</h2>MP collected and analyzed data. CE interpreted data and prepared manuscript. CE, MP and SW approved the final version of the manuscript.</section></section><section><section><h2>Data availability statement</h2>All relevant data are presented in the manuscript</section></section><section><section><h2>Financial support</h2>None.</section></section><section><section><h2>Conflict of interest</h2>None.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"10 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Striking Elevation of Alpha- Fetoprotein During Acute Transient Myopathy Following Yttrium-90 Trans-Arterial Radioembolization","authors":"Arjan Deol, Jonathan Lindquist, Katherine Marchak, J.P. Norvell, Leigh Casadaban","doi":"10.1016/j.jhep.2025.09.031","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.031","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>LC and JN conceived of the idea. AD wrote the manuscript. KM, JL, JN, AD, LC reviewed the manuscript.</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>Original data sets for this study are not publicly available. The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Data are located in controlled access data storage within the University of Colorado.</section></section><section><section><h2>Financial support</h2>None</section></section><section><section><h2>Conflict of interest</h2>Author Jonathan Lindquist has received grants from GE Corporation (CERRAF), Adient Medical (PREVENT-PE Trial), Inari Medical (CLOUT and FLASH registries, PEERLESS and DEFIANCE trials), AstraZeneca (EMERALD Y90 Trial), Society of Interventional Radiology Foundation (PAVM Registry), Philips Inc. (Excimer Laser IVC Filter Retrieval Registry), and SIRTEX Inc. (RESIN Registry). He has received consulting fees from Inari Medical, Endoshape Inc., Boston Scientific Corp., TriSalus Life Sciences, and</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"114 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma","authors":"Shengying Qian, Yong He","doi":"10.1016/j.jhep.2025.09.030","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.030","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors’ contributions</h2>SQ &amp; YH conceived and wrote the manuscript.</section></section><section><section><h2>Financial Support</h2>This work was sponsored by the National Science and Technology Innovation 2030 Major Program (2024ZD0530604) and the National Key Research and Development Program of China (2023YFA1800804).</section></section><section><section><h2>Conflicts of interest</h2>The authors declare no competing interests.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"102 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?","authors":"Thierry Thévenot, Maxime Desmarets, Grégory Tio","doi":"10.1016/j.jhep.2025.10.004","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.10.004","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Writing assistance</h2>Fiona Ecarnot revised the English for payment.</section></section><section><section><h2>Authors' contributions</h2><strong>Drafting of the manuscript</strong>: Thevenot T and Desmarets M. <strong>Statistical analysis</strong>: Tio G, Desmarets M.</section></section><section><section><h2>Financial support</h2>The original study was supported by a grant from the French Ministry of Health (PHRC-16-0015, Clinical trial number: NCT03069131) and by Alfasigma laboratories (Bologna, Italy) for partial financial support</section></section><section><section><h2>Competing Interests</h2>The authors of this Letter declare that they do not have any conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"86 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.","authors":"Pratibha Garg, Nipun Verma, Rajiv Jalan","doi":"10.1016/j.jhep.2025.10.003","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.10.003","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Uncited reference</h2>5..</section></section><section><section><h2>Authors' contributions</h2>Conceptualization: NV, RJ, Analysis: PG, Writing original draft: PG, NV, RJ, Writing-review and edits: RJ, NV</section></section><section><section><h2>Data availability statement</h2>The data generated and analysed during the current study are included in this published article or available from the corresponding author on reasonable request.</section></section><section><section><h2>Financial support</h2>This study was partly supported by the Indian Council of Medical Research (ICMR, 5/4/3-1/Gastro/2022-NCD-11 and NCD/Adhoc/129/2021-22 awarded to NV).</section></section><section><section><h2>Conflict of interest</h2>RJ: has research collaborations with Yaqrit. He is a founder of Yaqrit limited, a spin out company from University College London (<span><span>www.yaqrit.com</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>). He has also co-founded Cyberliver Ltd (<span><span>www.cyberliver.com</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>). Other authors declare no conflicts of interest.</section></section><section><section><h2>Acknowledgement</h2>None</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"12 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort","authors":"Luis Téllez, Jesús Donate, Antonio Guerrero, Idoia Agulleiro Beraza, Diego San Martín, Edilmar Alvarado, Víctor Echevarría, Ángela Puente, Javier Zamora, Susana del Prado, Andrés Tenes, Guillem Balagué, Bàrbara Vidal, Cristina Geli, Miguel Ángel Rodríguez-Gandía, Anna Baiges, Anna Brujats, Daniel López-Herrera Rodríguez, Santiago Fernández-Gordón Sánchez, José Ignacio Fortea, Agustín Albillos","doi":"10.1016/j.jhep.2025.09.011","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.011","url":null,"abstract":"<h3>Background &amp; aims</h3>Portopulmonary hypertension (PoPH) is a severe complication of cirrhosis and portal hypertension. In 2022, the European Task Force revised the diagnostic criteria for pulmonary arterial hypertension (PAH), defining early stages by a mean pulmonary arterial pressure (mPAP) of 20.5-24.5 mmHg and pulmonary vascular resistance (PVR) &gt;2 Wood units. We evaluated the predictive prognostic value of these revised criteria in cirrhotic patients.<h3>Methods</h3>In this longitudinal, multicenter, observational cohort, 428 adults with cirrhosis and portal hypertension underwent right-heart catheterization between 2015 and 2023 and were stratified into five groups: normal, early-PoPH, classic-PoPH, post-capillary pulmonary hypertension, and unclassified profiles. All-cause mortality was analyzed by multivariable Cox regression and competing-risk models, with liver transplantation as an intercurrent event.<h3>Results</h3>Over a median follow-up time of 20.0 months (IQR 8.0 -36.0), three-year survival rates were 76.7%, 49.5%, and 42.0% in the normal mPAP, early-PoPH, and classic-PoPH, respectively. After adjustment for age, sex, liver function, and portal-hypertension severity, both early-PoPH (HR 3.5 [1.9 -6.3], p &lt;0.01) and classic-PoPH (HR 4.5 [2.6 -7.6], p &lt;0.01) remained independent predictors of mortality versus normal mPAP; these associations persisted in competing-risk analysis, whereas post-capillary pulmonary hypertension and unclassified groups did not differ from the normal mPAP cohort.<h3>Conclusion</h3>Applying the 2022 ESC/ERC definitions of PAH identifies a subset of patients with cirrhosis with early-stage PoPH, characterized by mild pulmonary vascular resistance elevation, who nevertheless face a markedly increased risk of death, emphasizing the need for systematic screening and early targeted intervention.<h3>IMPACT AND IMPLICATIONS</h3>Portopulmonary hypertension (PoPH) is a severe and often overlooked complication of cirrhosis. Using the updated 2022 ESC/ERS diagnostic criteria, this multicenter study identified a previously unrecognized subgroup of cirrhotic patients with early-stage PoPH, defined by mildly elevated pulmonary vascular resistance and mean pulmonary artery pressure. Despite their subtle hemodynamic changes, these patients showed significantly reduced survival, independent of liver disease severity. These results highlight the prognostic relevance of early PoPH and suggest that applying the new criteria may help refine risk stratification and guide closer follow-up or earlier consideration of targeted interventions in selected patients.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"26 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioartificial Liver System for Liver Failure: A Therapeutic UTOpiA on the Horizon","authors":"Jingqi Wu, Lijian Hui","doi":"10.1016/j.jhep.2025.10.002","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.10.002","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Uncited reference</h2>[1].</section></section><section><section><h2>Authors’ contributions</h2>Both authors contributed equally to the writing of this editorial.</section></section><section><section><h2>Financial support</h2>This project was supported by the Shanghai Science and Technology Committee (25J32800100).</section></section><section><section><h2>Conflict of interest</h2>L.H. is the founder of Hexaell Biotech, serves as a member of the Board of Directors for the International Society for Stem Cell Research (ISSCR), and is the President of the Chinese Society for Cell and Gene Therapy (CSCGT).Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"11 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetically engineered pig-to-human liver xenotransplantation","authors":"Wenjie Zhang, Qingxiang Xu, Kaixiang Xu, Runqiu Jiang, Shouyu Wang, Meijuan Zheng, Nian Liu, Deling Jiao, Zhangding Wang, Jian Ge, Xianfu Lu, Guoqiang Li, Fan Huang, Lei Liu, Yin Yin, Yang Liu, Jianxiong Guo, Kai Liu, Hong-Jiang Wei, Beicheng Sun","doi":"10.1016/j.jhep.2025.08.044","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.08.044","url":null,"abstract":"<h3>Background</h3>The advent of genetically edited porcine-to-human xenotransplantation has predominantly focused on cardiac and renal applications, with no reported cases of porcine-to-human liver xenotransplantation. This study presents the world’s first successful genetically modified pig auxiliary liver xenotransplantation in a living human, achieving an unprecedented survival of 171 days, and provides valuable insights into the critical factors influencing the procedure’s success.<h3>Methods</h3>A genetically modified pig liver, incorporating 10 targeted gene edits, was transplanted as an auxiliary organ into a patient with large hepatocellular carcinoma in the right hepatic lobe, which was initially deemed ineligible for curative resection. Liver function, metabolic, and coagulation markers were closely monitored throughout the perioperative period.<h3>Results</h3>For the first 31 days post-transplant, no hyperacute or acute rejection, infections, or significant complications were observed, and the patient’s hepatic and renal functions remained stable. Early postoperative coagulopathy, as indicated by elevated D-dimer and fibrin degradation products, was successfully managed through anticoagulant therapy. However, on postoperative day 38, the auxiliary liver was removed due to xenotransplantation-associated thrombotic microangiopathy (xTMA). Subsequent management with eculizumab and plasma exchange successfully resolved the xTMA. Unfortunately, repeated upper gastrointestinal hemorrhage ultimately led to the patient's death on day 171.<h3>Conclusions</h3>This study demonstrates the feasibility of auxiliary porcine liver xenotransplantation as a bridging approach to human to liver transplantation. Postoperative xTMA presents a significant challenge to long-term success, highlighting the need for further research to improve xenotransplantation outcomes.<h3>Impact and implications</h3>This study reports the world’s first auxiliary xenotransplantation from a 10-gene-edited pig to a living human recipient - distinct from previous studies involving brain-dead donors.The donor liver was engineered using a 10-gene editing platform, including the knockout of xenoantigen genes and the knock-in of seven human transgenes for immune and coagulation compatibility - pushing the boundaries of synthetic biology in clinical transplantation.The porcine graft exhibited metabolically active liver function, bile secretion, and coagulation correction, demonstrating not only survival but clinically meaningful function.Our work documents, for the first time, xenotransplantation-associated thrombotic microangiopathy (xTMA) in a living human recipient, with comprehensive immunological and histopathological analysis - critical knowledge for the field.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"9 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Beyond a Single Snapshot: Considerations for PEth-Guided Subclassification of Steatotic Liver Disease\"","authors":"Federica Tavaglione, Rohit Loomba","doi":"10.1016/j.jhep.2025.09.028","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.09.028","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>All authors contributed to the drafting and revision of this letter.</section></section><section><section><h2>Financial support</h2>The authors did not receive any financial support to produce this letter.</section></section><section><section><h2>Conflict of interest</h2>The authors declare no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"50 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}